AMAnnette Madison

Annette Madison

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annette Madison has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine

    by Ignacio Fuentes, Marlín Solórzano, Annette Madison, Joel Falcón, Catalina Ruiz, Joaquín Viñambres, Rodolfo Cabello, Nicole Lustig, Lorena Mosso, Rodrigo Jaimovich, et al.

    Introduction: Intermediate‐risk papillary thyroid carcinoma (PTC) accounts for 40%–60% of newly diagnosed PTC and comprises a heterogeneous group with variable recurrence risk. The benefit of postoperative radioactive iodine (RAI) remains uncertain. Objectives: To describe features, response‐to‐therapy outcomes, and ATA 2025 recurrence‐risk redistribution in patients with ATA 2015 intermediate‐risk PTC managed without adjuvant RAI. Design: Retrospective cohort study. Methods: Adults (≥ 18 years) with ATA 2015 intermediate‐risk PTC treated with total thyroidectomy (TT) or thyroid lobectomy (TL), with/without lymph node dissection, and followed for ≥ 1 year were included. Omission of postoperative RAI was based on histopathology, cervical ultrasound (US), serum thyroglobulin (Tg), and anti‐thyroglobulin antibodies (TgAb) measured within 6 months postoperatively. TL patients required negative US. TT patients required negative US plus Tg < 1 ng/mL if TgAb‐negative, or stable/declining TgAb if positive. Response to therapy was assessed using ATA 2015 dynamic risk stratification and reassessed with ATA 2025 criteria. Results: Ninety‐nine patients were included; 84 (84.8%) were women, the mean age was 40.2 ± 13.3 years, and the median follow‐up was 4.8 years. Microscopic extrathyroidal extension was present in 51 (51.5%), lymph node metastases in 37 (37.4%), and extranodal extension in 4 (4.0%). By ATA 2015, 67 (67.7%) had an excellent response and 32 (32.3%) an indeterminate response; no incomplete responses or structural recurrences occurred. ATA 2025 reclassified 3 (3.0%) as low risk, 39 (39.4%) as low‐intermediate, 52 (52.5%) as high‐intermediate, and 5 (5.1%) as high risk. Conclusions: Selected intermediate‐risk PTC patients managed without adjuvant RAI had excellent mid‐term outcomes, supporting a risk‐adapted de‐escalation strategy.

  • Persistent elevated thyroglobulin revealing Struma ovarii in a patient treated for papillary thyroid carcinoma: A case report

    by Nicole Lustig, Leticia Rincón, Juan Carlos Quintana, Virginia Iturrieta, Ignacio Fuentes, Marlín Solórzano, Annette Madison, Lorena Mosso, Rodrigo Jaimovich, José Miguel Domínguez